Impaired glutamate homeostasis in the nucleus accumbens in human cocaine addiction.


Journal

Molecular psychiatry
ISSN: 1476-5578
Titre abrégé: Mol Psychiatry
Pays: England
ID NLM: 9607835

Informations de publication

Date de publication:
09 2021
Historique:
received: 07 01 2020
accepted: 18 06 2020
revised: 16 06 2020
pubmed: 1 7 2020
medline: 1 2 2022
entrez: 1 7 2020
Statut: ppublish

Résumé

Cocaine addiction is characterized by overwhelming craving for the substance, which drives its escalating use despite adverse consequences. Animal models suggest a disrupted glutamate homeostasis in the nucleus accumbens to underlie addiction-like behavior. After chronic administration of cocaine, rodents show decreased levels of accumbal glutamate, whereas drug-seeking reinstatement is associated with enhanced glutamatergic transmission. However, due to technical obstacles, the role of disturbed glutamate homeostasis for cocaine addiction in humans remains only partially understood, and accordingly, no approved pharmacotherapy exists. Here, we applied a tailored proton magnetic resonance spectroscopy protocol that allows glutamate quantification within the human nucleus accumbens. We found significantly reduced basal glutamate concentrations in the nucleus accumbens in cocaine-addicted (N = 26) compared with healthy individuals (N = 30), and increased glutamate levels during cue-induced craving in cocaine-addicted individuals compared with baseline. These glutamatergic alterations, however, could not be significantly modulated by a short-term challenge of N-acetylcysteine (2400 mg/day on 2 days). Taken together, our findings reveal a disturbed accumbal glutamate homeostasis as a key neurometabolic feature of cocaine addiction also in humans. Therefore, we suggest the glutamatergic system as a promising target for the development of novel pharmacotherapies, and in addition, as a potential biomarker for a personalized medicine approach in addiction.

Identifiants

pubmed: 32601455
doi: 10.1038/s41380-020-0828-z
pii: 10.1038/s41380-020-0828-z
doi:

Substances chimiques

Glutamic Acid 3KX376GY7L
Cocaine I5Y540LHVR

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

5277-5285

Informations de copyright

© 2020. The Author(s), under exclusive licence to Springer Nature Limited.

Références

Asensio S, Romero MJ, Palau C, Sanchez A, Senabre I, Morales JL, et al. Altered neural response of the appetitive emotional system in cocaine addiction: an fMRI Study. Addict Biol. 2010;15:504–16.
pubmed: 20579005
Goldstein RZ, Alia-Klein N, Tomasi D, Zhang L, Cottone LA, Maloney T, et al. Is decreased prefrontal cortical sensitivity to monetary reward associated with impaired motivation and self-control in cocaine addiction? Am J Psychiatry. 2007;164:43–51.
pubmed: 17202543 pmcid: 2435056
Preller KH, Herdener M, Schilbach L, Stämpfli P, Vonmoos M, Ingold N, et al. Functional changes of the reward system underlie blunted response to social gaze in cocaine users. Proc Natl Acad Sci USA. 2014;111:2842–7.
pubmed: 24449854 pmcid: 3932870
Kirschner M, Sladky R, Haugg A, Stämpfli P, Jehli E, Hodel M, et al. Self-regulation of the dopaminergic reward circuit in cocaine users with mental imagery and neurofeedback. EBioMedicine. 2018;37:489–98.
pubmed: 30377073 pmcid: 6286189
Haber SN, Knutson B. The reward circuit: linking primate anatomy and human imaging. Neuropsychopharmacology. 2009;35:4–26.
pmcid: 3055449
Kalivas PW. The glutamate homeostasis hypothesis of addiction. Nat Rev Neurosci. 2009;10:561–72.
pubmed: 19571793
Lüscher C, Malenka RC. Drug-evoked synaptic plasticity in addiction: from molecular changes to circuit remodeling. Neuron. 2011;69:650–63.
pubmed: 21338877 pmcid: 4046255
Scofield MD, Kalivas PW. Astrocytic dysfunction and addiction: consequences of impaired glutamate homeostasis. Neuroscientist. 2014;20:610–22.
pubmed: 24496610 pmcid: 4913887
Mulholland PJ, Chandler LJ, Kalivas PW. Signals from the fourth dimension regulate drug relapse. Trends Neurosci. 2016;39:472–85.
pubmed: 27173064 pmcid: 4930682
McFarland K, Lapish CC, Kalivas PW. Prefrontal glutamate release into the core of the nucleus accumbens mediates cocaine-induced reinstatement of drug-seeking behavior. J Neurosci. 2003;23:3531–7.
pubmed: 12716962 pmcid: 6742291
Quednow BB, Herdener M. Human pharmacology for addiction medicine: from evidence to clinical recommendations. Prog Brain Res. 2016;224:227–50.
pubmed: 26822361
Hulka LM, Scheidegger M, Vonmoos M, Preller KH, Baumgartner MR, Herdener M, et al. Glutamatergic and neurometabolic alterations in chronic cocaine users measured with (1) H-magnetic resonance spectroscopy. Addict Biol. 2014;21:205–17.
pubmed: 25600822
Schmaal L, Veltman DJ, Nederveen A, van den Brink W, Goudriaan AE. N-Acetylcysteine normalizes glutamate levels in cocaine-dependent patients: a Randomized Crossover Magnetic Resonance Spectroscopy Study. Neuropsychopharmacology. 2012;37:2143–52.
pubmed: 22549117 pmcid: 3398721
Yang S, Salmeron BJ, Ross TJ, Xi Z-X, Stein EA, Yang Y. Lower glutamate levels in rostral anterior cingulate of chronic cocaine users—a (1)H-MRS study using TE-averaged PRESS at 3 T with an optimized quantification strategy. Psychiatry Res. 2009;174:171–6.
pubmed: 19906515 pmcid: 2788034
Martinez D, Slifstein M, Nabulsi N, Grassetti A, Urban NBL, Perez A, et al. Imaging glutamate homeostasis in cocaine addiction with the metabotropic glutamate receptor 5 positron emission tomography radiotracer [(11)C]ABP688 and magnetic resonance spectroscopy. Biol Psychiatry. 2014;75:165–71.
pubmed: 24035345
de Graaf RA. In vivo NMR spectroscopy. 2nd ed. Chichester, UK: John Wiley & Sons Ltd; 2007.
Neto LL, Oliveira E, Correia F, Ferreira AG. The human nucleus accumbens: where is it? A stereotactic, anatomical and magnetic resonance imaging study. Neuromodulation. 2008;11:13–22.
pubmed: 22150987
Dreher W, Leibfritz D. New method for the simultaneous detection of metabolites and water in localized in vivo 1H nuclear magnetic resonance spectroscopy. Magn Reson Med. 2005;54:190–5.
pubmed: 15968666
Hock A, MacMillan EL, Fuchs A, Kreis R, Boesiger P, Kollias SS, et al. Non-water-suppressed proton MR spectroscopy improves spectral quality in the human spinal cord. Magn Reson Med. 2012;69:1253–60.
pubmed: 22745036
MacMillan EL, Chong DGQ, Dreher W, Henning A, Boesch C, Kreis R. Magnetization exchange with water and T1 relaxation of the downfield resonances in human brain spectra at 3.0 T. Magn Reson Med. 2011;65:1239–46.
pubmed: 21394768
Zoelch N, Hock A, Henning A. Quantitative magnetic resonance spectroscopy at 3T based on the principle of reciprocity. NMR Biomed. 2018;55:e3875.
Yagen B, Hernandez O, Bend JR, Cox RH. Synthesis and relative stereochemistry of the four mercapturic acids derived from styrene oxide and N-acetylcysteine. Chem Biol Interact. 1981;34:57–67.
pubmed: 7460077
McClure EA, Gipson CD, Malcolm RJ, Kalivas PW, Gray KM. Potential role of N-acetylcysteine in the management of substance use disorders. CNS Drugs. 2014;28:95–106.
pubmed: 24442756 pmcid: 4009342
American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision. American Psychiatric Association Press: Washington, DC, 2000.
Provencher SW. Estimation of metabolite concentrations from localized in vivo proton NMR spectra. Magn Reson Med. 1993;30:672–9.
pubmed: 8139448
Friston KJ, Ashburner JT, Kiebel SJ, Nichols TE, Penny WD. Statistical parametric mapping. 1st ed. London: Academic Press; 2006.
Mardikian PN, LaRowe SD, Hedden S, Kalivas PW, Malcolm RJ. An open-label trial of N-acetylcysteine for the treatment of cocaine dependence: a pilot study. Prog Neuro-Psychopharmacol Biol Psychiatry. 2007;31:389–94.
Holdiness MR. Clinical pharmacokinetics of N-acetylcysteine. Clin Pharmacokinet. 1991;20:123–34.
pubmed: 2029805
Brown H, Prescott R. Applied mixed models in medicine. Chichester, UK: John Wiley & Sons; 2006.
Oz G, Alger JR, Barker PB, Bartha R, Bizzi A, Boesch C, et al. Clinical proton MR spectroscopy in central nervous system disorders. Radiology. 2014;270:658–79.
pubmed: 24568703
Knackstedt LA, Melendez RI, Kalivas PW. Ceftriaxone restores glutamate homeostasis and prevents relapse to cocaine seeking. Biol Psychiatry. 2010;67:81–84.
pubmed: 19717140 pmcid: 2795043
Trantham-Davidson H, LaLumiere RT, Reissner KJ, Kalivas PW, Knackstedt LA. Ceftriaxone normalizes nucleus accumbens synaptic transmission, glutamate transport, and export following cocaine self-administration and extinction training. J Neurosci. 2012;32:12406–10.
pubmed: 22956831 pmcid: 3465971
Reissner KJ, Gipson CD, Tran PK, Knackstedt LA, Scofield MD, Kalivas PW. Glutamate transporter GLT-1 mediates N-acetylcysteine inhibition of cocaine reinstatement. Addict Biol. 2015;20:316–23.
pubmed: 24612076
Moran MM, McFarland K, Melendez RI, Kalivas PW, Seamans JK. Cystine/glutamate exchange regulates metabotropic glutamate receptor presynaptic inhibition of excitatory transmission and vulnerability to cocaine seeking. J Neurosci. 2005;25:6389–93.
pubmed: 16000629 pmcid: 1413952
Bowers MS, McFarland K, Lake RW, Peterson YK, Lapish CC, Gregory ML, et al. Activator of G protein signaling 3: a gatekeeper of cocaine sensitization and drug seeking. Neuron. 2004;42:269–81.
pubmed: 15091342 pmcid: 3619420
Zaehle T, Bauch EM, Hinrichs H, Schmitt FC, Voges J, Heinze H-J, et al. Nucleus accumbens activity dissociates different forms of salience: evidence from human intracranial recordings. J Neurosci. 2013;33:8764–71.
pubmed: 23678119 pmcid: 6618843
Léna I, Parrot S, Deschaux O, Muffat-Joly S, Sauvinet V, Renaud B, et al. Variations in extracellular levels of dopamine, noradrenaline, glutamate, and aspartate across the sleep-wake cycle in the medial prefrontal cortex and nucleus accumbens of freely moving rats. J Neurosci Res. 2005;81:891–9.
pubmed: 16041801
Robinson TE, Berridge KC. The neural basis of drug craving: an incentive-sensitization theory of addiction. Brain Res Rev. 1993;18:247–91.
pubmed: 8401595
Batten SR, Pomerleau F, Quintero J, Gerhardt GA, Beckmann JS. The role of glutamate signaling in incentive salience: second-by-second glutamate recordings in awake Sprague-Dawley rats. J Neurochem. 2018;145:276–86.
pubmed: 29315659 pmcid: 5980676
O’Gorman Tuura R, Warnock G, Ametamey S, Treyer V, Noeske R, Buck A, et al. Imaging glutamate redistribution after acute N-acetylcysteine administration: a simultaneous PET/MR study. NeuroImage. 2019;184:826–33.
pubmed: 30296554
Schulte MHJ, Wiers RW, Boendermaker WJ, Goudriaan AE, van den Brink W, van Deursen DS, et al. The effect of N-acetylcysteine and working memory training on cocaine use, craving and inhibition in regular cocaine users: correspondence of lab assessments and Ecological Momentary Assessment. Addict Behav. 2017;79:24–31.
pubmed: 29241082
Womersley JS, Townsend DM, Kalivas PW, Uys JD. Targeting redox regulation to treat substance use disorder using N-acetylcysteine. Eur J Neurosci. 2019;50:2538–51.
pubmed: 30144182
Olive MF, Cleva RM, Kalivas PW, Malcolm RJ. Glutamatergic medications for the treatment of drug and behavioral addictions. Pharm Biochem Behav. 2012;100:801–10.

Auteurs

Etna J E Engeli (EJE)

Centre for Addictive Disorders, Department of Psychiatry, Psychotherapy and Psychosomatics, Psychiatric Hospital, University of Zurich, Zurich, Switzerland. etna.engeli@bli.uzh.ch.

Niklaus Zoelch (N)

Institute for Biomedical Engineering, University of Zurich and Swiss Federal Institute of Technology Zurich, Zurich, Switzerland.
Institute of Forensic Medicine, University of Zurich, Zurich, Switzerland.
Department of Psychiatry, Psychotherapy and Psychosomatics, Psychiatric Hospital, University of Zurich, Zurich, Switzerland.

Andreas Hock (A)

Institute for Biomedical Engineering, University of Zurich and Swiss Federal Institute of Technology Zurich, Zurich, Switzerland.
Department of Psychiatry, Psychotherapy and Psychosomatics, Psychiatric Hospital, University of Zurich, Zurich, Switzerland.

Carlos Nordt (C)

Centre for Addictive Disorders, Department of Psychiatry, Psychotherapy and Psychosomatics, Psychiatric Hospital, University of Zurich, Zurich, Switzerland.

Lea M Hulka (LM)

Centre for Addictive Disorders, Department of Psychiatry, Psychotherapy and Psychosomatics, Psychiatric Hospital, University of Zurich, Zurich, Switzerland.

Matthias Kirschner (M)

Centre for Addictive Disorders, Department of Psychiatry, Psychotherapy and Psychosomatics, Psychiatric Hospital, University of Zurich, Zurich, Switzerland.
Montreal Neurological Institute, McGill University, Montreal, QC, Canada.

Milan Scheidegger (M)

Department of Psychiatry, Psychotherapy and Psychosomatics, Psychiatric Hospital, University of Zurich, Zurich, Switzerland.

Fabrizio Esposito (F)

Department of Medicine, Surgery and Dentistry, Scuola Medica Salernitana, University of Salerno, Baronissi, Salerno, Italy.

Markus R Baumgartner (MR)

Centre for Forensic Hair Analytics, Zurich Institute of Forensic Medicine, University of Zurich, Zurich, Switzerland.

Anke Henning (A)

Institute for Biomedical Engineering, University of Zurich and Swiss Federal Institute of Technology Zurich, Zurich, Switzerland.
Zurich Centre for Integrative Human Physiology, University of Zurich, Zurich, Switzerland.
Max-Planck-Institute for Biological Cybernetics, Tuebingen, Germany.
Institute of Physics, Ernst-Moritz-Arndt University, Greifswald, Germany.

Erich Seifritz (E)

Department of Psychiatry, Psychotherapy and Psychosomatics, Psychiatric Hospital, University of Zurich, Zurich, Switzerland.
Zurich Centre for Integrative Human Physiology, University of Zurich, Zurich, Switzerland.
Neuroscience Centre Zurich, University of Zurich and Swiss Federal Institute of Technology Zurich, Zurich, Switzerland.

Boris B Quednow (BB)

Zurich Centre for Integrative Human Physiology, University of Zurich, Zurich, Switzerland.
Neuroscience Centre Zurich, University of Zurich and Swiss Federal Institute of Technology Zurich, Zurich, Switzerland.
Experimental and Clinical Pharmacopsychology, Department of Psychiatry, Psychotherapy and Psychosomatics, Psychiatric Hospital, University of Zurich, Zurich, Switzerland.

Marcus Herdener (M)

Centre for Addictive Disorders, Department of Psychiatry, Psychotherapy and Psychosomatics, Psychiatric Hospital, University of Zurich, Zurich, Switzerland.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH